Skip to main content

Table 5 Change in the central foveal thickness every month from baseline till the last visit

From: Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

  RBZ (n = 69) (%) BEV (n = 66) (%) BSR (n = 67) (%) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
Month 1       
 Decreased 52(75.4) 42 (63.6) 42 (62.7) 0.18 0.77 0.12
 Stable 10(14.5) 17 (25.8) 15 (22.4)
 Increased 7 (10.1) 7 (10.6) 10(14.9)
 n 69 66 67
Month 2       
 Decreased 29 (42.0) 23 (34.8) 21(31.3) 0.29 0.80 0.18
 Stable 26 (37.7) 25 (37.9) 28(41.8)
 Increased 14 (20.3) 18 (27.3) 18(26.9)
 n 69 66 67
Month 3       
 Decreased 18 (30.5) 21 (32.8) 24 (40.7) 0.92 0.36 0.31
 Stable 26 (44.1) 26 (40.6) 22 (37.3)
 Increased 15 (25.4) 17 (26.6) 13 (22)
 n 59 64 59
Month 4       
 Decreased 15 (31.9) 15 (27.3) 8 (27.6) 0.90 0.92 0.85
 Stable 17 (36.2) 26 (47.3) 14 (48.3)
 Increased 15 (31.9) 14 (25.5) 7 (24.1)
 n 47 55 29
Month 5       
 Decreased 10 (27.8) 13 (27.7) 6 (33.3) 0.75 0.63 0.81
 Stable 18 (50.0) 26 (55.3) 6 (33.3)
 Increased 8 (22.2) 8 (17.0) 6 (33.3)
 n 36 47 18
Month 6       
 Decreased 17 (39.5) 18 (34.0) 6 (24.0) 0.98 0.15 0.22
 Stable 17 (39.5) 28 (52.8) 12 (48.0)
 Increased 9 (20.9) 7 (13.2) 7 (28.0)
 n 43 53 25
Last visit       
 Decreased 19 (36.5) 16 (36.4) 6 (30.0) 0.98 0.54 0.56
 Stable 16 (30.8) 13 (29.5) 6 (30.0)
 Increased 17 (32.7) 15 (34.1) 8 (40.0)
 n 52 44 20